BioLineRx Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BLRX Nasdaq 2836 www.biolinerx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioLineRx Ltd.

BLRX: First Quarter 2026 Results - May 28th, 2026 9:17 am
BioLineRx Shares Advance After First Patient Enrolled in GLIX1 Cancer Study (BLRX) - May 27th, 2026 5:53 am
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update - May 27th, 2026 5:00 am
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting - May 22nd, 2026 5:00 am
BioLineRx to Report First Quarter 2026 Results on May 27, 2026 - May 20th, 2026 5:00 am
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts - May 19th, 2026 5:00 am
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) - Apr 28th, 2026 5:00 am
Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma - Apr 8th, 2026 12:30 am
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) - Mar 26th, 2026 5:00 am
BioLine Rx Ltd (BLRX) Full Year 2025 Earnings Call Highlights: Navigating Challenges and ... - Mar 25th, 2026 7:01 pm
BLRX: Full Year 2025 Results - Mar 23rd, 2026 11:06 am
BioLineRx Reports 2025 Financial Results and Provides Corporate Update - Mar 23rd, 2026 5:00 am
BioLineRx to Report 2025 Annual Results on March 23, 2026 - Mar 16th, 2026 5:00 am
BioLine Rx Ltd (BLRX) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... - Nov 28th, 2025 6:00 pm
BLRX: Stem Cell Mobilization Presentation at ASH - Nov 25th, 2025 8:09 am
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 24th, 2025 5:00 am
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025 - Nov 18th, 2025 5:00 am
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types - Nov 17th, 2025 5:00 am
BLRX: A Venture into GBM - Sep 30th, 2025 6:46 am
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers - Sep 29th, 2025 5:00 am